9 recruiting, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 14 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Recruiting 9, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Suspended 1 |
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
Follow XL092: new trials by email Literature Review of XL092 trials Research Report on XL092
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors Zanzalintinib - Cancer, Pediatric Cancer | Phase 1 | Not yet recruiting | Exelixis | 18 | 2026-09-30 | 2026-08-19 |
| Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Hepatocellular Carcinoma, Cirrhosis | Phase 1 / Phase 2 | Recruiting | Devalingam Mahalingam | 59 | 2026-03-30 | 2026-10-23 |
| Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma Zanzalintinib, Ipilimumab, Nivolumab - Metastatic Soft-tissue Sarcoma | Phase 1 | Suspended | Washington University School of Medicine | 18 | 2026-01-05 | 2026-09-04 |
| Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma Zanzalintinib, Eribulin - Advanced Leiomyosarcoma, Adipocytic Sarcoma | Phase 1 | Recruiting | Washington University School of Medicine | 18 | 2025-10-22 | 2026-06-03 |
| Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer Zanzalintinib, Paclitaxel - Uterine Cancer, Endometrial Cancer | Phase 1 | Recruiting | Washington University School of Medicine | 36 | 2025-10-17 | 2026-10-13 |
| Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC Zanzalintinib, Cetuximab, Pembrolizumab - Head and Neck Neoplasms, Carcinoma, Squamous Cell | Phase 1 | Recruiting | University of Chicago | 36 | 2025-09-29 | 2025-12-02 |
| Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) Belzutifan, Zanzalintinib - Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 140 | 2025-07-20 | 2026-10-27 |
| XL092 and Cemiplimab in BRAF WT Thyroid Cancer Cemiplimab, XL092 - Anaplastic Thyroid Cancer, Thyroid Cancer | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 12 | 2025-06-03 | 2026-10-05 |
| Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) Zanzalintinib - Hepatic Impairment, Moderate Hepatic Impairment | Phase 1 | Recruiting | Exelixis | 20 | 2025-05-13 | 2025-06-22 |
| A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors XB628, Zanzalintinib - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | Exelixis | 303 | 2025-05-01 | 2026-06-24 |
| Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) zanzalintinib, AB521, Nivolumab - Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | Phase 1 | Terminated | Exelixis | 25 | 2024-01-25 | 2025-06-12 |
| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors Zanzalintinib, Nivolumab, Ipilimumab - Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Exelixis | 1394 | 2021-12-14 | 2026-10-01 |
| A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors XL092, Atezolizumab, Avelumab - Neoplasm Malignant, Renal Cell Carcinoma | Phase 1 | Active not recruiting | Exelixis | 325 | 2019-03-20 | 2024-11-19 |
| A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) Atezolizumab, Cobimetinib, RO6958688 - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 314 | 2017-12-27 | 2026-05-12 |
Carcinoma, Renal Cell (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Sarcoma (2) · Brain Neoplasms (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Fibrosis (1) · Head and Neck Neoplasms (1) · Neoplasm Recurrence, Local (1) · Nervous System Neoplasms (1)
Exelixis (6) · Washington University School of Medicine (3) · Devalingam Mahalingam (1) · Hoffmann-La Roche (1) · Merck Sharp & Dohme LLC (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Chicago (1)
United States (13) · France (4) · Spain (4) · United Kingdom (4) · Australia (3) · Israel (3) · Belgium (2) · Germany (2) · Italy (2) · Poland (2) · South Korea (2) · Austria (1) · Chile (1) · Czechia (1) · Netherlands (1)
Ari Rosenberg, MD (1) · David G Mutch, M.D. (1) · Devalingam Mahalingam (1) · Mia C Weiss, M.D. (1) · Mia Weiss, M.D. (1) · Siddharth Sheth, DO MPH (1)
2017 (1), 2023 (1), P30CA060553 (1), P50CA265793 (1)